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Abstract
Background: Lupus nephritis class III or IV is associated with a poor prognosis for both patient and renal survival.
Recommendations for the management of lupus nephritis have recently been established, and changing therapies
is recommended for patients who do not respond adequately to induction therapy. However, it remains a major
challenge to determine when to switch the treatment. In this study, we identified early prognostic factors capable
of predicting poor renal outcome as well as overall damage accrual in patients with lupus nephritis class III or IV.
Methods: Eighty patients with biopsy-proven lupus nephritis class III or IV were retrospectively recruited and
divided into two groups: those with complete renal response (CR) or non-CR at 3 years after induction therapy.
We investigated when clinical responses were obtained at each observational period from baseline to year 3.
Clinical responses were divided into three groups: CR, partial renal response (PR), and non-PR. Furthermore, patients
were assessed using the Systemic Lupus International Collaborating Clinics/American College of Rheumatology
Damage Index (SDI) and cumulative dose of corticosteroid for 3 years.
Results: Forty-four patients with CR and thirty-six with non-CR were enrolled. The cumulative CR rate was 85.0%.
PR rates of patients with CR were significantly higher than those with non-CR from week 12 (p < 0.01). We identified
the achievement of PR at 12 weeks as an independent predictor (OR 3.57, p = 0.03) by multivariate analysis. We next
divided all patients into two groups according to PR achievement at week 12. The cumulative CR rate of the
patients who achieved PR at week 12 was significantly higher than that of those who did not (96.5% vs 69.2%,
p < 0.001). Furthermore, a significantly higher SDI and cumulative dose of corticosteroid were seen in the
patients who did not achieve PR at week 12 than in those who did, regardless of their CR status, at year 3.
Conclusions: Lack of PR at week 12 predicts a lower likelihood of achieving CR at 3 years and a higher SDI.
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Background
Lupus nephritis (LN) is a common manifestation of sys-
temic lupus erythematosus (SLE) that contributes to sig-
nificant morbidity and mortality [1]. Although the
survival of patients with SLE has improved over the past
several decades, the 10-year survival rate is still lower
than that of age- and sex-matched healthy populations
[2]. The most important cause of late mortality is cumu-
lative organ damage [3]. Recently, the Joint European
League Against Rheumatism and European Renal Asso-
ciation–European Dialysis and Transplant Association
(EULAR/ERA-EDTA) published recommendations for
LN management. They proposed that a partial renal re-
sponse (PR) should be preferably achieved within
6 months after the initiation of treatment, and that treat-
ment should be switched for patients without PR [4].
Furthermore, a treat-to-target approach developed to
prevent flares and damage caused by SLE [5] suggests
that patients should be properly monitored and therapy
should be adjusted at reasonable time intervals. Given
reports that early renal damage correlates with future
damage accrual and is a predictor of a worse prognosis
[6], an earlier decision to switch initial treatment for pa-
tients with poor renal response would be desirable in
clinical settings. Although authors of a few reports have
focused on the association between renal response and
prognosis [7–11], there have been no reports on the early
renal response as a predictive factor for overall damage ac-
crual in patients with LN class III or IV. In the present
study, we comprehensively analyzed patients with biopsy-
proven LN class III or IV to determine early prognostic
factors capable of predicting poor renal outcome as well
as overall damage accrual.
Methods
Patients
We initially assessed the eligibility of all 358 consecutive
Japanese patients with SLE who visited St. Marianna
University Hospital from 2003 through 2010 and met
the American College of Rheumatology classification cri-
teria [12]. Among these, we identified patients diagnosed
with class III or IV LN according to the International
Society of Nephrology/Renal Pathology Society (ISN/
RPS) classification [13] who had completed at least
3 years of observation. Of 88 patients with biopsy-
proven LN, 82 had LN class III or IV. Two of these were
lost to follow-up, and no patients died during the study
period, leaving eighty patients for final enrollment. This
study was approved by the ethics committee of St. Mar-
ianna University School of Medicine. Because this study
was conducted with a retrospective cohort design with-
out any samples taken besides those for clinical use,
written informed consent was not acquired, in accord-
ance with the guideline of Ministry of Health, Labour
and Welfare of Japan. We retrospectively observed clin-
ical characteristics, treatments, and clinical courses after
initial induction therapy.
Data collection
Clinical information was obtained from all patients at
baseline and at 2, 4, 8, 12, 24, 48, 96, and 144 weeks
(3 years) after initial induction therapy. The baseline
clinical information was collected at the time of renal bi-
opsy before initial induction therapy. Data gathered in-
cluded demographic features, treatment regimens, and
Systemic Lupus Erythematosus Disease Activity Index
(SLEDAI) scores [14]. PR and complete renal response
(CR) were defined on the basis of EULAR/ERA-EDTA
recommendations for LN [4], with CR defined as a urine
protein/creatinine ratio (UPCR) of 50 mg/mmol and
normal or near-normal (within 10% of normal glomeru-
lar filtration rate [GFR] if previously abnormal) renal
function and PR defined as a ≥50% reduction in protein-
uria and normal or near-normal GFR. We substituted
0.5 g/g creatinine for UPCR 50 mg/mmol [4]. Renal re-
lapse was defined as loss of CR status after achieving
CR. Additionally, we used the Systemic Lupus Inter-
national Collaborating Clinics/American College of
Rheumatology Damage Index (SDI) to assess systemic
damage accrual [15]. SDI was evaluated at baseline and
at 6 months and 1, 2, and 3 years after induction ther-
apy. We calculated the damage point presenting for at
least 6 months [15].
Prognostic factors for CR at 3 years
The primary endpoint was set as CR at 3 years after the
initiation of induction therapy. We divided the patients
into two groups based on whether they achieved this
endpoint, and then we compared them regarding base-
line demographic features, treatment regimens, and clin-
ical course after the initiation of treatment. Further, we
investigated when clinical responses were obtained dur-
ing each observational period from baseline to year 3.
Renal pathology
Patients underwent a renal biopsy before the initial in-
duction therapy. In all cases, specimens taken for light
microscopy were embedded in paraffin; sectioned; and
stained with Masson’s trichrome, hematoxylin and
eosin, periodic acid silver–methenamine, and periodic
acid–Schiff. Frozen tissue was cut into 5-μm sections
and incubated with fluoresceinated antisera to human
immunoglobulins (Ig) IgG, IgA, and IgM; complement
components C3, C4, and C1q; and fibrinogen. All patients
were diagnosed according to the ISN/RPS classification
[13] by light microscopy and immunofluorescence ana-
lysis. The activity index (AI) and the chronicity index
(CI) developed by Austin et al. [16] were scored.
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Morphological features of the standard AI and CI were
evaluated separately, namely endocapillary hypercellu-
larity, polymorphonuclear leukocyte infiltration, karyor-
rhexis/fibrinoid necrosis, cellular crescents, hyaline
deposits, interstitial inflammation, glomerular sclerosis,
fibrous crescents, tubular atrophy, and interstitial fibro-
sis. We measured the percentage of these features in in-
dividual patients.
Statistical analysis
Continuous values are shown as mean ± SD. Clinical
characteristics between the two groups were compared
using the nonparametric Mann-Whitney U test.
Frequencies of clinicopathological characteristics were
compared using the chi-square test. Cumulative CR
rates were calculated using the Kaplan-Meier method,
and differences between the two groups were tested
with a log-rank test. To identify independent parame-
ters that predict CR at 3 years after the initial therapy,
we performed multivariate analysis using initial charac-
teristics previously reported as predictors for good
renal outcome [17], treatment regimens, and PR at
12 weeks. We selected SLEDAI and complement com-
ponent CH50 levels as other covariates in multivariate
analysis because they differed significantly between CR
and non-CR patients at their baseline. Additionally, be-
cause therapeutic intervention may influence clinical
response, particularly intravenous cyclophosphamide
(IVCY) or mycophenolate mofetil (MMF) use [18, 19],
we performed multiple regression analysis with baseline
estimated glomerular filtration rate (eGFR), SLEDAI,
CH50 level, IVCY use, MMF use, and achievement of




We enrolled 80 patients and divided them into 2 groups
according to their CR status at 3 years after induction
therapy. At 3 years, 44 patients remained in CR and 36
did not. Demographic and clinical features of the pa-
tients at baseline are shown in Table 1. Among clinical
features at baseline, patients with CR had significantly
higher SLEDAI scores and lower CH50 levels (p < 0.01
and p = 0.02, respectively).
All patients received glucocorticoid therapy at an ini-
tial dose of 1.0 mg equivalent prednisolone (PSL)/kg/day
for 2–4 weeks. After initial therapy, PSL was tapered by
10% of the last dose or 10 mg, as determined by the at-
tending physician. Eight patients were treated with PSL
monotherapy, whereas others received immunosuppres-
sive agents as induction therapy, including IVCY, MMF,
or tacrolimus (TAC). The dose of IVCY ranged from
500 mg/2-week interval for six courses to 1000 mg/4-
week interval for six courses. MMF was started at an ini-
tial dose of 0.5–1.0 g/day and gradually increased to
2.0 g/day. TAC dose (1.5–3.0 mg/day) was precisely ad-
justed to a trough value of serum concentrations. After
six infusions of IVCY, patients were switched to azathio-
prine (AZA) at 100 mg/day while treatment with other
immunosuppressants (ISs) was continued as mainten-
ance therapy. Regarding initial treatment, PSL dose did
not differ markedly between the two groups (p = 0.07),
but a higher proportion of PSL monotherapy (p = 0.07)
was observed in patients with non-CR. There were no
remarkable differences between the two groups with re-
gard to treatment regimens or in renal pathological ana-
lysis, including ISN/RPS classification, morphological
features of LN, or AI and CI.
Renal response at each visit and CR status at year 3
We next focused on renal response. Table 2 shows the
percentage of patients achieving PR at each visit in the
two groups. A significantly higher proportion of patients
achieved PR in the CR than in the non-CR group from
weeks 12 to 96 (p = 0.03, p < 0.01, p = 0.01, and p < 0.01,
respectively). We further analyzed cumulative CR rates
(Fig. 1). The cumulative CR rate for all patients was
85.0%. When we divided all patients into PR (n = 54) or
non-PR (n = 26) at week 12, a significantly higher cumu-
lative CR rate was seen in patients with PR at week 12
than with non-PR (96.5% vs 69.2%, p < 0.001). Although
we conducted the same analysis of patients who
achieved PR or non-PR at weeks 24, 48, and 96 separ-
ately, a significant difference was not detected in cumu-
lative CR rates from the result for patients with PR or
non-PR at week 12. Furthermore, a cutoff of 50.0% re-
duction of proteinuria from baseline at week 12 showed
79% sensitivity and 17% specificity (area under the ROC
curve 0.73) for CR achievement at year 3. The analysis
using 50% reduction of proteinuria at 3 months for SDI
of 0 over 3 years showed 53% sensitivity and 79% specifi-
city (area under the ROC curve 0.66). We next analyzed
the relapse-free rate depending on PR achievement at
week 12. We found 49 patients (90.7%) among those
with PR at week 12 experienced CR during the 3 years,
and 21 (42.9%) relapsed. Further, 16 patients (61.5%) in
non-PR experienced CR, and 11 (68.5%) relapsed. A
significantly higher relapse-free rate was found by
the Kaplan-Meier method in those with PR at week
12 (p = 0.03) (Fig. 1b). Achieving PR at week 12 may
indicate a higher likelihood of achieving CR and a
lower likelihood of relapse for 3 years.
Identification of prognostic factors for CR at 3 years
We performed multiple regression analysis with baseline
eGFR level, SLEDAI score, CH50 level, IVCY use, MMF
use, and the achievement of PR at 12 weeks for the
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dependent variable CR at 3 years (Table 3). We statisti-
cally identified the achievement of PR at 12 weeks as an
independent predictor (OR 3.57, p = 0.03). Although it
has been well investigated that baseline renal function is
an important predictor, we failed to show its signifi-
cance. Because our patients had relatively mild renal
dysfunction at baseline (75.0 ± 29.6 ml/minute/
1.73 m2), we performed the analysis again by using the
covariate of eGFR greater or less than 60 ml/minute/
1.73 m2. The OR was 1.63 (95% confidence interval
0.64–4.33, p = 0.3).
Renal outcomes and damage accrual
We next classified all patients into four groups on the
basis of PR status at week 12 and CR status at year 3.
Their actual degree of improvement of proteinuria
(percent change from baseline) is shown as follows
(mean ± SD): patients with PR/CR (−90.6 ± 85.9%), PR/
non-CR (−82.0 ± 79.3%), non-PR/CR (+16.0 ± 22.5%),
and non-PR/non-CR (−17.2 ± 12.1%). Baseline clinical
and renal pathological features of these groups are
shown in Table 4. A significantly higher proportion of
patients who experienced both PR at week 12 and CR
at year 3 was female (p = 0.05) and had shorter dur-
ation (p = 0.09), but no other significant differences in
clinical or renal pathological features at baseline were
identified. Patients with PR/CR tended to have higher




Patients who achieved PR, n (%) p Value
CR at year 3
(n = 44)
Non-CR at year 3
(n = 36)
2 23 (52.5) 17 (47.2) 0.08
4 26 (59.1) 18 (50.0) 0.41
8 31 (70.4) 18 (50.0) 0.06
12 34 (77.3) 20 (55.5) 0.03
24 38 (86.4) 20 (55.5) <0.01
48 40 (90.1) 25 (69.4) 0.01
96 40 (90.1) 25 (69.4) 0.01
PR Partial renal response, CR Complete renal response
Table 1 Baseline clinical and renal pathological features of
lupus nephritis patients with or without complete renal
response at 3 years after induction therapy





Female sex, n (%) 40 (90.9) 27 (75.0) 0.32
Age, years 39.7 ± 13.1 38.3 ± 11.5 0.43
BMI, kg/m2 22.1 ± 2.9 21.7 ± 3.1 0.31
Systolic blood pressure,
mmHg
128.3 ± 16.7 130.0 ± 18.3 0.34
Diastolic blood pressure,
mmHg
80.1 ± 13.2 79.9 ± 13.6 0.57
Disease duration, years 5.9 ± 8.0 7.7 ± 7.2 0.23
SLEDAI 16.3 ± 4.7 13.4 ± 4.9 <0.01
SDI 0.4 ± 0.6 0.5 ± 0.6 0.26
Proteinuria, g/g creatinine 2.6 ± 2.2 3.1 ± 1.8 0.14
eGFR, ml/minute 72.9 ± 27.4 77.6 ± 32.3 0.27
Anti-dsDNA antibody, IU/ml 212 ± 300 155 ± 259 0.26
Anticardiolipin antibody, IU/ml 23.5 ± 30.6 15.4 ± 25.6 0.12
Lupus anticoagulant-positive,
n (%)
9 (20.5) 3 (8.3) 0.13
CH50, U/ml 16.1 ± 8.6 21.4 ± 12.4 0.02
Prednisolone, mg/day 45.9 ± 14.9 41.1 ± 14.1 0.07
Induction therapy, n (%)
IVCY 25 (56.8) 15 (44.4) 0.34
MMF 8 (18.2) 3 (11.1) 0.23
Tacrolimus 7 (15.9) 6 (19.4) 0.96
PSL monotherapy 2 (4.5) 6 (16.7) 0.07
Others 2 (4.5) 6 (16.7) 0.07
Renal pathological findings
ISN/RPS classification
III (A) or III (A/C), n (%) 18 (40.9) 9 (25.0) 0.13
III (A) or III (A/C) + V, n (%) 4 (9.1) 6 (16.7) 0.34
IV (A) or IV (A/C), n (%) 14 (31.8) 15 (41.7) 0.41
IV (A) or IV (A/C) + V, n (%) 8 (18.2) 6 (16.7) 0.92
Endocapillary hypercellularity, % 41.2 ± 29.5 43.0 ± 33.1 0.27
Leukocyte infiltration, % 1.9 ± 5.5 1.4 ± 4.0 0.34
Subendothelial hyaline
deposits, %
31.2 ± 32.7 30.7 ± 29.3 0.43
Fibrinoid necrosis/karyorrhexis, % 6.9 ± 12.4 15.3 ± 28.0 0.17
Cellular crescents, % 8.3 ± 7.3 10.6 ± 21.8 0.18
Interstitial inflammation, % 1.2 ± 4.8 2.1 ± 7.1 0.44
Glomerular sclerosis, % 3.7 ± 8.2 6.9 ± 9.1 0.25
Fibrous crescents, % 1.6 ± 3.1 1.1 ± 4.2 0.43
Tubular atrophy, % 3.8 ± 6.3 6.3 ± 6.1 0.14
Table 1 Baseline clinical and renal pathological features of
lupus nephritis patients with or without complete renal
response at 3 years after induction therapy (Continued)
Interstitial fibrosis, % 4.6 ± 7.2 7.1 ± 6.0 0.26
Activity index 5.1 ± 3.1 5.9 ± 4.1 0.21
Chronicity index 1.3 ± 0.2 1.8 ± 1.6 0.12
Abbreviations: SLEDAI Systemic Lupus Erythematosus Disease Activity Index,
SDI Systemic Lupus International Collaborating Clinics/American College of
Rheumatology Damage Index, dsDNA Double-stranded DNA, IVCY Intravenous
cyclophosphamide, MMF Mycophenolate mofetil, ISN/RPS International Society
of Nephrology/Renal Pathology Society, BMI Body mass index, eGFR Estimated
glomerular filtration rate, PSL Prednisolone
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serological activity and SLEDAI at baseline than others.
This may have influenced the physician’s therapeutic
choice for aggressive therapy. More than 70% of pa-
tients with PR/CR and non-PR/CR received IVCY or
MMF as an induction therapy, compared with less than
55% of those with non-PR/non-CR. Furthermore, more
than 60% of patients with PR/CR received AZA or
MMF as maintenance therapy, compared with 43.8% of
those with non-PR/non-CR. Although the difference
was not statistically significant, the small difference of
the intensity of IS therapy may have resulted in our
findings that patients with greater disease burden at
baseline (higher serologic activity, SLEDAI, and LN
class III or IV findings) belonged to the PR/CR group.
We next evaluated the percentage of patients treated
aggressively after the induction therapy, including cor-
ticosteroid dose-up, IS addition, IS dose-up, or IS
change (Fig. 2). As a result, patients with PR/CR were
not more aggressively treated after induction therapy
than those in the other groups.
We analyzed SDI at year 3 among the four groups
(Fig. 3a). Higher damage accrual was seen in patients
who did not achieve both PR at week 12 and CR at year
3. Even when CR was obtained at year 3, patients who
failed to achieve PR at week 12 had higher SDI values
than those who did achieve PR at week 12 (p < 0.01).
Collectively, SDI at year 3 depended primarily on PR
status at week 12 and not on CR status at year 3.
Among the three other groups, furthermore, the high-
est cumulative dose of corticosteroid for 3 years was
seen in patients with both non-PR at week 12 and non-
CR at year 3 (Fig. 3b). Compared with patients who
achieved CR at year 3, those achieving PR at week 12
had a lower steroid dose than those who did not (p =
0.03). To investigate the impact of corticosteroid use
on damage, we divided SDI into two categories (cor-
ticosteroid-related and not corticosteroid-related) ac-
cording to the method of Gladman et al. [20]. Because
the highest SDI was seen in the non-PR/non-CR group,
we found the main damage was related to the cortico-
steroid (Fig. 4a). Because the cumulative PSL dose was
increased (Fig. 3b), its damage also accumulated. Fur-
thermore, we additionally investigated the renal damage
at year 3 in the four groups (Fig. 4b). Although a
slightly lower eGFR was found in the non-PR/CR group
and the non-PR/non-CR group, there was no significant
difference in renal damage. Early renal response and
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Fig. 1 Cumulative CR rate and renal relapse-free rate for 3 years
after induction therapy. a Cumulative CR rate is significantly higher
in patients with PR at week 12 than in those with non-PR (HR 2.66,
95% confidence interval 2.13–5.47, p < 0.001). b Relapse-free rate is
significantly higher in patients with PR at week 12 than in those
with non-PR (HR 1.98, 95% confidence interval 1.10–5.35, p = 0.03).
CR Complete renal response; PR Partial renal response
Table 3 Multivariate analysis for predictors of patients with
complete renal response at 3 years after induction therapy
Parameters OR 95% confidence interval p Value
PR at 12 weeks 3.57 1.16–12.1 0.03
eGFR, ml/minute/1.73 m2 1.00 0.98–1.02 0.62
SLEDAI 0.94 0.82–1.07 0.48
CH50, U/ml 1.03 0.97–1.09 0.21
MMF use 4.43 0.78–30.6 0.09
IVCY use 1.32 0.38–4.58 0.62
Abbreviations: PR Partial renal response, SLEDAI Systemic Lupus Erythematosus
Disease Activity Index, MMF Mycophenolate mofetil, IVCY Intravenous
cyclophosphamide, eGFR Estimated glomerular filtration rate
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Table 4 Baseline clinical and renal pathological features of patients with systemic lupus erythematosus, depending on renal response at
week 12 and year 3
Renal response at week 12/year 3
Baseline characteristics PR/CR (n = 34) PR/non-CR (n = 20) Non-PR/CR (n = 10) Non-PR/non-CR (n = 16) p Value
Female sex, n (%) 33 (97.1) 15 (75.0) 7 (70.0) 12 (75.0) 0.05
Age, years 38.9 ± 12.8 38.8 ± 11.5 42.6 ± 14.5 37.8 ± 11.9 0.82
BMI, kg/m2 22.3 ± 3.1 21.6 ± 2.9 21.9 ± 2.9 21.9 ± 3.5 0.94
Systolic blood pressure, mmHg 128.8 ± 17.7 130.3 ± 15.4 126.5 ± 14.0 129.9 ± 22.1 0.91
Diastolic blood pressure, mmHg 80.8 ± 14.1 79.9 ± 13.3 77.4 ± 9.4 79.9 ± 14.6 0.86
Disease duration, years 4.6 ± 7.4 6.3 ± 6.5 10.8 ± 8.9 9.6 ± 7.9 0.09
SLEDAI 16.9 ± 4.5 14.1 ± 5.7 13.8 ± 4.9 12.6 ± 3.8 0.15
SDI 0.3 ± 0.6 0.5 ± 0.5 0.6 ± 0.7 0.6 ± 0.7 0.33
Proteinuria, g/g creatinine 2.4 ± 2.1 3.1 ± 1.9 2.9 ± 2.5 3.1 ± 1.7 0.47
eGFR, ml/minute/1.73 m2 73.5 ± 27.0 78.3 ± 32.2 70.9 ± 29.9 76.8 ± 33.4 0.84
Anti-dsDNA antibody, IU/ml 234.5 ± 332.1 106.3 ± 104.59 139.3 ± 150.1 212.9 ± 364.9 0.21
Anticardiolipin antibody, IU/ml 27.6 ± 14.1 19.1 ± 32.4 11.9 ± 7.7 10.5 ± 11.5 0.13
Lupus anticoagulant-positive, n (%) 8 (23.5) 2 (10.0) 1 (10.0) 1 (6.2) 0.34
CH50, U/ml 27.6 ± 14.1 19.1 ± 32.4 11.9 ± 7.7 10.5 ± 11.5 0.12
Prednisolone, mg/day 46.5 ± 14.0 41.5 ± 14.6 44.3 ± 18.6 40.7 ± 14.3 0.58
Induction therapy, n (%)
IVCY 20 (58.8) 10 (50.0) 5 (50.0) 5 (33.3) 0.36
MMF 5 (14.7) 0 (0.0) 3 (30.0) 3 (18.8) 0.18
Tacrolimus 5 (14.7) 4 (20.0) 2 (20.0) 2 (12.5) 0.94
PSL monotherapy 2 (5.8) 4 (20.0) 0 (0.0) 2 (12.5) 0.15
Others 2 (5.8) 2 (10.0) 0 (0.0) 4 (25.0) 0.16
Maintenance therapy, n (%)
Azathioprine 14 (41.2) 4 (20.0) 3 (30.0) 3 (18.8) 0.33
MMF 8 (23.5) 3 (15.0) 3 (30.0) 4 (25.0) 0.84
Tacrolimus 6 (17.6) 6 (30.0) 2 (20.0) 3 (18.8) 0.71
PSL monotherapy 4 (11.8) 4 (20.0) 1 (10.0) 1 (6.3) 0.66
Others 2 (5.9) 3 (15.0) 1 (10.0) 5 (31.3) 0.17
Renal pathological findings, n (%)
ISN/RPS classification
III (A) or III (A/C) 13 (38.2) 5 (27.9) 4 (40.0) 4 (25.0) 0.65
III (A) or III (A/C) + V 4 (11.8) 2 (10.0) 1 (10.0) 3 (18.8) 0.94
IV (A) or IV (A/C) 12 (35.3) 9 (45.0) 3 (30.0) 6 (37.5) 0.93
IV (A) or IV (A/C) + V 6 (17.6) 3 (15.0) 2 (20.0) 3 (18.8) 1.00
Endocapillary hypercellularity, % 31.2 ± 21.2 40.3 ± 13.1 41.3 ± 10.1 48.1 ± 8.2 0.64
Leukocyte infiltration, % 2.0 ± 3.5 1.1 ± 2.4 2.9 ± 1.3 2.2 ± 1.3 0.35
Subendothelial hyaline deposits, % 40.1 ± 10.1 29.1 ± 12.4 27.9 ± 12.7 38.1 ± 11.3 0.42
Fibrinoid necrosis/karyorrhexis, % 7.0 ± 10.1 6.0 ± 11.2 6.1 ± 10.4 5.9 ± 11.4 0.53
Cellular crescents, % 7.1 ± 7.2 8.1 ± 6.1 7.2 ± 7.4 8.8 ± 7.1 0.52
Interstitial inflammation, % 1.0 ± 4.8 1.2 ± 4.8 1.2 ± 4.8 1.2 ± 4.8 0.84
Glomerular sclerosis, % 3.9 ± 7.2 3.7 ± 8.1 3.2 ± 7.1 3.3 ± 6.2 0.71
Fibrous crescents, % 1.6 ± 3.0 1.5 ± 2.8 2.0 ± 1.1 1.7 ± 2.9 0.46
Tubular atrophy, % 5.2 ± 5.1 3.2 ± 5.1 3.1 ± 5.1 3.0 ± 6.1 0.27
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Discussion
In this study, we found that achievement of PR at week
12 was associated with low systemic damage at year 3,
regardless of CR achievement. Further studies should
address whether switching therapy is beneficial.
Most patients with SLE develop LN. LN impacts clin-
ical outcomes in SLE, both directly by target organ dam-
age and indirectly through complications of therapy,
resulting in increased risks for renal failure, cardiovascu-
lar disease, and death [21]. The most important cause of
late mortality in SLE is damage accrual, and SDI evalu-
ation is a valuable means of predicting its prognosis [3].
Several factors contribute to the development of damage
in patients with SLE [22]. To reduce systemic damage
caused by disease activity, patients should be properly
monitored, and therapy should be adjusted according to
clinical status [5]. Because renal damage early in the dis-
ease course predicts worse prognosis, initial induction
treatment should be promptly switched for patients who
do not respond as expected. Among other factors, cor-
ticosteroid use has been established clearly to cause
damage [23, 24]. Recently, Joo et al. demonstrated LN is
associated with increased corticosteroid-associated
damage compared with non-LN [24]. It is very import-
ant to aim for the lowest corticosteroid dose needed to
control disease activity, especially for patients with LN
[5]. In our study, patients who failed to achieve PR at
week 12 tended to have higher SDI over 3 years. Its
main damage was associated with corticosteroid use.
Persistent LN activity leads these patients to be given a
higher dose of corticosteroid. Because prevention of
damage accrual should be a major therapeutic goal in
SLE [5], PR at week 12 may be a clinically important
target.
According to the EULAR/ERA-EDTA recommenda-
tions for LN management, PR should be achieved within
6 months after the start of induction treatment [4]. Our
results, however, showed that more patients experienced
PR by 6 months after induction treatment than by
3 months, and the cumulative CR rate at 3 years did not
significantly differ between these two groups (p = 0.2).
Further, only four patients (5.0% of all patients) who did
not achieve PR at 3 months finally achieved PR at
6 months. Given that most patients who responded at
6 months after the start of induction treatment had
already responded at 3 months, observation until
6 months might not be particularly beneficial.
Our results suggest that if patients do not achieve PR
by week 12, they will be less likely to experience CR in
the future and would accrue more renal damage, regard-
less of CR status at year 3. Our findings support a previ-
ous report by Rahman et al., who noted that early renal
damage correlated with future damage accrual [6]. In an
experimental lupus murine model, an earlier response to
treatment was associated with an improved survival rate
compared with a later response [25]. We speculate that
the disease process may be less severe in fast responders
and that these patients can sustain a good clinical course
in the long term.
Authors of several previous reports investigated renal
outcomes in patients with LN class III or IV by focusing
on renal responses [7–11]. Illei et al. [7] and Mok et al.
[8] evaluated mainly patients with LN treated with cyclo-
phosphamide and reported that renal flares were com-
mon in patients with a sustained partial response
compared with those with a complete response. Korbet
et al. [10] investigated patients with LN treated with
Table 4 Baseline clinical and renal pathological features of patients with systemic lupus erythematosus, depending on renal response at
week 12 and year 3 (Continued)
Interstitial fibrosis, % 5.2 ± 6.2 4.1 ± 6.1 4.3 ± 6.3 4.0 ± 5.2 0.95
Activity index 5.3 ± 2.8 5.1 ± 2.9 5.4 ± 3.1 6.0 ± 2.1 0.27
Chronicity index 1.4 ± 0.1 1.3 ± 0.2 1.4 ± 0.1 1.8 ± 1.6 0.88
Abbreviations: SLEDAI Systemic Lupus Erythematosus Disease Activity Index, SDI Systemic Lupus International Collaborating Clinics/American College of
Rheumatology Damage Index, dsDNA Double-stranded DNA, IVCY Intravenous cyclophosphamide, MMF Mycophenolate mofetil, ISN/RPS International Society of
Nephrology/Renal Pathology Society, BMI Body mass index, eGFR Estimated glomerular filtration rate, PSL Prednisolone, CR Complete renal response, PR Partial
renal response
PR PR non-PR non-PR
Renal response at
Week 12:
CR non-CR CR non-CRYear 3:


















Fig. 2 Intensification of therapy after induction therapy for 3 years.
The percentage of patients treated aggressively, including corticosteroid
dose-up, IS addition, IS dose-up, or IS change, depending on the
renal response at week 12 and year 3, is shown. IS Immunosuppressant,
CR Complete renal response, PR Partial renal response
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plasmapheresis and concluded that >50% reduction of
proteinuria at 6 months predicted 15-year survival. Re-
cently, Tamirou et al. [11] reported 10-year follow-up of
the MAINTAIN Nephritis Trial and concluded that early
decrease of proteinuria at 3 months showed a high posi-
tive predictive value but a low negative predictive value
for good renal outcome. The MAINTAIN study com-
prised a European cohort, and a direct comparison with
our data would not be appropriate; however, although
the primary outcome was defined differently, a higher
negative predictive value for early decrease of protein-
uria was obtained in our results than in Tamirou et al.’s
(62% vs 21%, respectively). Our results may suggest use-
ful information for switching therapy in patients with
lack of PR by 12 weeks. Furthermore, we also investi-
gated the accrual of damage in all patients, depending
on their early clinical response and future outcome. Be-
cause patients with LN should be closely managed to
reduce damage accrual [5], our findings show the
a
PR PR non-PR non-PR
Renal response at
Week 12:
CR non-CR CR non-CRYear 3:
































PR PR non-PR non-PR
Renal response at
Week 12:
CR non-CR CR non-CRYear 3:
(n=34) (n=20) (n=10) (n=16)
 p=0.19
b
Fig. 4 Component of SDI and renal damage at 3 years. a
Percentage of corticosteroid-related or not corticosteroid-related
damage of SDI in four groups. Corticosteroid-related damage was
increased in patients with non-PR/non-CR. b The renal damage at
year 3 in the four groups is shown. There is no significant difference in
renal damage. CR Complete renal response, PR Partial renal response,
SDI Systemic Lupus International Collaborating Clinics/American




















































Fig. 3 Systemic damage accrual and cumulative dose of prednisolone
dose for 3 years after induction therapy. a Patients were divided into
four groups on the basis of renal response at week 12 and year 3. A
significantly lower SDI was seen in patients achieving both PR at week
12 and CR at year 3 than in patients who failed to achieve PR at week
12, regardless of CR achievement at year 3 (p < 0.01 and p < 0.01,
respectively). b Compared with patients who achieved CR at year 3,
the cumulative steroid dose was significantly lower in patients who
achieved PR at week 12 than in those who did not (p = 0.01). SDI
Systemic Lupus International Collaborating Clinics/American College of
Rheumatology Damage Index, CR Complete renal response, PR Partial
renal response, PSL Prednisolone
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importance of early renal response in clinical settings.
However, careful assessment would be needed regard-
ing whether induction therapy should be modified in
patients without PR at week 12, because renal response
to cyclophosphamide sometimes takes longer (up to
12 months).
The present study is limited by its single-center, retro-
spective design and relatively short observational period.
The differences in disease findings and intensity of ther-
apy among the groups may have failed to show statistical
significance, owing to the small sample size. The base-
line clinical characteristics in the sample were quite vari-
able, and not all the induction therapies were standard
regimens. The IS doses were reduced in some patients
because of safety concerns. Some patients refused the
use of ISs. Therefore, these limitations may make our
findings less convincing. The results of the study may
not be applicable to the other population that received
the standard regimens. Furthermore, the patients were
all Japanese, and our data may not be generalizable to
other ethnic groups. Renal response may differ depend-
ing on ethnic and racial background. Therefore, a multi-
center, prospective study is required to confirm our
findings. Our suggestion to switch induction therapy in
patients without achieving PR at week 12 requires fur-
ther analysis to determine whether switching treatment
could reduce future damage in these patients.
Conclusions
We found that achievement of PR at week 12 was asso-
ciated with low systemic damage at year 3, regardless of
CR achievement. Further studies should address whether
switching therapy at 12 weeks if a PR is not reached re-
sults in an improved CR rate and a lower SDI score.
Abbreviations
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